CHARACTERIZATION OF BONE-MARROW STROMAL CELLS FROM MULTIPLE-MYELOMA

被引:33
|
作者
GREGORETTI, MG
GOTTARDI, D
GHIA, P
BERGUI, L
MERICO, F
MARCHISIO, PC
CALIGARISCAPPIO, F
机构
[1] UNIV TURIN, DIPARTIMENTO SCI BIOMED & ONCOL UMANA, SEZ ISTOL, TURIN, ITALY
[2] UNIV TURIN, SEZ CLIN, TURIN, ITALY
关键词
BONE MARROW; MYELOMA; STROMAL CELLS; ADHESION MOLECULES; INTEGRINS; CULTURES;
D O I
10.1016/0145-2126(94)90067-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have cultured multiple myeloma (MM) bone marrow (BM) stromal cells that are able to sustain the in vitro growth of monoclonal B-cells. Our aim was to evaluate which adhesion molecules are expressed and which extracellular matrix proteins are produced by these cells and whether they differ from the stromal cells that can be grown under the same experimental conditions from the BM of monoclonal gammopathies of undetermined significance (MGUS) and of normal donors. MM BM stromal cells that support malignant B-cell development have a striking proliferative ability that is absent in MGUS and normal donors of the same age group and are formed by four major different cell populations. Two kinds of HLA-DR+, CD10+ fibroblast-like cells can be recognized through the expression (or the lack) of alpha-smooth muscle actin isoform; further, macrophages and osteoclasts can be identified. Fibroblast-like cells that express alpha-smooth muscle actin isoform, often organized along stress fibers in a periodic fashion, may be considered as myofibroblasts. Fibroblast-like cells react strongly with antibodies to CD54 (ICAM-1), integrin beta 1 beta 3, beta 5 and some of associated alpha chains. Integrin beta 1 is diffusely exposed on the surface while beta 3 is clustered in focal contacts in association with vinculin. A still undetermined subpopulation of fibroblasts is highly positive for alpha nu beta 5that is clustered at focal contacts as shown by association with stress fiber termini and by interference reflection microscopy. A major difference between MM and normal donor BM stromal cells involves lower deposition and simpler organization of the extracellular matrix proteins (fibronectin, laminin, collagen type IV) deposited by MM fibroblast-like cells. CD14+ macrophages from MM, MGUS and normal donor BM are CD11a+ (alpha L), CD11b+ (alpha M), CD11c+ (alpha X), CD54+ (ICAM-1), CD56+ (N-CAM), beta 1 and beta 2 (CD18) integrin positive. The integrin beta 1is diffusely expressed on the surface, while beta 2 is concentrated in podosomes. MM osteoclasts show a weak diffuse staining with CD54 and CD56 MoAbs; beta 1 integrin has a diffuse surface expression, while beta 3 integrin is concentrated in the podosomes. Normal donor osteoclasts are CD54- and the staining with CD56 is barely visible. These findings lead us to suggest that the microenvironment provided by MM BM may be significantly different from that of normal BM indicating its potential role in controlling the local proliferation and differentiation of malignant B-lineage cells.
引用
收藏
页码:675 / 682
页数:8
相关论文
共 50 条
  • [21] BONE-MARROW FIBROSIS IN MULTIPLE-MYELOMA - REPLY
    KRZYZANIAK, RL
    BUSS, DH
    COOPER, MR
    WELLS, HB
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1988, 90 (06) : 753 - 754
  • [22] BONE-MARROW ANGIOGENESIS AND PROGRESSION IN MULTIPLE-MYELOMA
    VACCA, A
    RIBATTI, D
    RONCALI, L
    RANIERI, G
    SERIO, G
    SILVESTRIS, F
    DAMMACCO, F
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (03) : 503 - 508
  • [23] BONE-MARROW MICROENVIRONMENT AND THE PROGRESSION OF MULTIPLE-MYELOMA
    CALIGARISCAPPIO, F
    GREGORETTI, MG
    MERICO, F
    GOTTARDI, D
    GHIA, P
    PARVIS, G
    BERGUI, L
    [J]. LEUKEMIA & LYMPHOMA, 1992, 8 (1-2) : 15 - 22
  • [24] ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MULTIPLE-MYELOMA
    BALLESTER, OF
    [J]. SEMINARS IN ONCOLOGY, 1993, 20 (05) : 67 - 71
  • [25] BONE-MARROW TRANSPLANTATION IN MULTIPLE-MYELOMA - REPORT FROM THE EUROPEAN COOPERATIVE GROUP FOR BONE-MARROW TRANSPLANTATION
    GAHRTON, G
    TURA, S
    FLESCH, M
    GRATWOHL, A
    GRAVETT, P
    LUCARELLI, G
    MICHALLET, M
    REIFFERS, J
    RINGDEN, O
    VANLINT, MT
    VERNANT, JP
    ZWAAN, FE
    [J]. BLOOD, 1987, 69 (04) : 1262 - 1264
  • [26] AUTOLOGOUS BONE-MARROW TRANSPLANTATION THERAPY FOR MULTIPLE-MYELOMA
    ANDERSON, KC
    BARUT, BA
    RITZ, J
    FREEDMAN, AS
    NADLER, LM
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, SUPPL NO 51, VOL 43, 1989: PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON MULTIPLE MYELOMA - BIOLOGY, PATHOPHYSIOLOGY, PROGNOSIS AND TREATMENT, 1989, : 157 - 163
  • [27] HISTOLOGY AND IMMUNOHISTOLOGY OF BONE-MARROW BIOPSY IN MULTIPLE-MYELOMA
    PILERI, S
    POGGI, S
    BAGLIONI, P
    MONTANARI, M
    SABATTINI, E
    GALIENI, P
    TAZZARI, PL
    GOBBI, M
    CAVO, M
    FALINI, B
    STEIN, H
    TURA, S
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, SUPPL NO 51, VOL 43, 1989: PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON MULTIPLE MYELOMA - BIOLOGY, PATHOPHYSIOLOGY, PROGNOSIS AND TREATMENT, 1989, : 52 - 59
  • [28] BONE-MARROW PATTERN AND CLINICAL STAGING IN MULTIPLE-MYELOMA
    CARBONE, A
    VOLPE, R
    MANCONI, R
    POLETTI, A
    TIRELLI, U
    MONFARDINI, S
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1987, 65 (04) : 502 - 503
  • [29] TREATMENT OF MULTIPLE-MYELOMA BY ALLOGENEIC BONE-MARROW TRANSPLANTATION
    HEYLL, A
    AUL, C
    SOHNGEN, D
    MECKENSTOCK, G
    ARNING, M
    WURM, R
    SCHMITT, G
    SCHNEIDER, W
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1991, 116 (22) : 852 - 856
  • [30] ALLOGENEIC BONE-MARROW TRANSPLANTATION IN PATIENTS WITH MULTIPLE-MYELOMA
    GAHRTON, G
    TURA, S
    BELANGER, C
    CAVO, M
    CHAPVIS, B
    FERRANT, A
    FLESCH, M
    GORE, M
    GRATWOHL, A
    GRAVETT, PJ
    HARROUSEAU, JL
    LINDEBERG, A
    LJUNGMAN, P
    LOWENBERG, B
    LUCARELLI, G
    MICHALLET, M
    REIFFERS, J
    RINGDEN, O
    VANLINT, MT
    VERNANT, JP
    SALLERFORS, B
    SIMONSSON, B
    TOIVANEN, A
    TROUSSARD, X
    VERDONCK, LF
    VOLIN, L
    ZWAAN, FE
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, SUPPL NO 51, VOL 43, 1989: PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON MULTIPLE MYELOMA - BIOLOGY, PATHOPHYSIOLOGY, PROGNOSIS AND TREATMENT, 1989, : 182 - 185